155 related articles for article (PubMed ID: 14718607)
41. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein.
Döppenschmitt S; Spahn-Langguth H; Regårdh CG; Langguth P
J Pharm Sci; 1999 Oct; 88(10):1067-72. PubMed ID: 10514357
[TBL] [Abstract][Full Text] [Related]
42. Furanocoumarin derivatives in Kampo extract medicines inhibit cytochrome P450 3A4 and P-glycoprotein.
Iwanaga K; Hayashi M; Hamahata Y; Miyazaki M; Shibano M; Taniguchi M; Baba K; Kakemi M
Drug Metab Dispos; 2010 Aug; 38(8):1286-94. PubMed ID: 20463004
[TBL] [Abstract][Full Text] [Related]
43. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption--theoretical approach.
Ito K; Kusuhara H; Sugiyama Y
Pharm Res; 1999 Feb; 16(2):225-31. PubMed ID: 10100307
[TBL] [Abstract][Full Text] [Related]
44. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.
Lown KS; Bailey DG; Fontana RJ; Janardan SK; Adair CH; Fortlage LA; Brown MB; Guo W; Watkins PB
J Clin Invest; 1997 May; 99(10):2545-53. PubMed ID: 9153299
[TBL] [Abstract][Full Text] [Related]
45. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4.
Bhardwaj RK; Glaeser H; Becquemont L; Klotz U; Gupta SK; Fromm MF
J Pharmacol Exp Ther; 2002 Aug; 302(2):645-50. PubMed ID: 12130727
[TBL] [Abstract][Full Text] [Related]
46. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens.
von Richter O; Burk O; Fromm MF; Thon KP; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2004 Mar; 75(3):172-83. PubMed ID: 15001968
[TBL] [Abstract][Full Text] [Related]
47. Transport characteristics of ebastine and its metabolites across human intestinal epithelial Caco-2 cell monolayers.
Imamura Y; Shimizu K; Yamashita F; Yamaoka K; Takakura Y; Hashida M
Biol Pharm Bull; 2001 Aug; 24(8):930-4. PubMed ID: 11510488
[TBL] [Abstract][Full Text] [Related]
48. P-glycoprotein-mediated efflux of indinavir metabolites in Caco-2 cells expressing cytochrome P450 3A4.
Hochman JH; Chiba M; Yamazaki M; Tang C; Lin JH
J Pharmacol Exp Ther; 2001 Jul; 298(1):323-30. PubMed ID: 11408558
[TBL] [Abstract][Full Text] [Related]
49. Significance of Basal Membrane Permeability of Epithelial Cells in Predicting Intestinal Drug Absorption.
Yoshitomo A; Asano S; Hozuki S; Tamemoto Y; Shibata Y; Hashimoto N; Takahashi K; Sasaki Y; Ozawa N; Kageyama M; Iijima T; Kazuki Y; Sato H; Hisaka A
Drug Metab Dispos; 2023 Mar; 51(3):318-328. PubMed ID: 36810197
[TBL] [Abstract][Full Text] [Related]
50. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data.
Benet LZ; Cummins CL; Wu CY
Curr Drug Metab; 2003 Oct; 4(5):393-8. PubMed ID: 14529371
[TBL] [Abstract][Full Text] [Related]
51. Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans.
Becquemont L; Glaeser H; Drescher S; Hitzl M; Simon N; Murdter TE; Heinkele G; Hofmann U; Schaefer C; Burk O; Verstuyft C; Eichelbaum M; Fromm MF
Clin Pharmacol Ther; 2006 May; 79(5):449-60. PubMed ID: 16678547
[TBL] [Abstract][Full Text] [Related]
52. Transport of HIV-protease inhibitors across 1 alpha,25di-hydroxy vitamin D3-treated Calu-3 cell monolayers: modulation of P-glycoprotein activity.
Patel J; Pal D; Vangal V; Gandhi M; Mitra AL
Pharm Res; 2002 Nov; 19(11):1696-703. PubMed ID: 12458676
[TBL] [Abstract][Full Text] [Related]
53. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells.
Takano M; Hasegawa R; Fukuda T; Yumoto R; Nagai J; Murakami T
Eur J Pharmacol; 1998 Oct; 358(3):289-94. PubMed ID: 9822896
[TBL] [Abstract][Full Text] [Related]
54. Enhanced transport of P-glycoprotein substrate saquinavir in presence of thiolated chitosan.
Föger F; Kafedjiiski K; Hoyer H; Loretz B; Bernkop-Schnürch A
J Drug Target; 2007 Feb; 15(2):132-9. PubMed ID: 17365284
[TBL] [Abstract][Full Text] [Related]
55. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.
Huisman MT; Smit JW; Wiltshire HR; Hoetelmans RM; Beijnen JH; Schinkel AH
Mol Pharmacol; 2001 Apr; 59(4):806-13. PubMed ID: 11259625
[TBL] [Abstract][Full Text] [Related]
56. Midazolam metabolism by modified Caco-2 monolayers: effects of extracellular protein binding.
Fisher JM; Wrighton SA; Calamia JC; Shen DD; Kunze KL; Thummel KE
J Pharmacol Exp Ther; 1999 May; 289(2):1143-50. PubMed ID: 10215698
[TBL] [Abstract][Full Text] [Related]
57. CYP1A1 induction and CYP3A4 inhibition by the fungicide imazalil in the human intestinal Caco-2 cells-comparison with other conazole pesticides.
Sergent T; Dupont I; Jassogne C; Ribonnet L; van der Heiden E; Scippo ML; Muller M; McAlister D; Pussemier L; Larondelle Y; Schneider YJ
Toxicol Lett; 2009 Feb; 184(3):159-68. PubMed ID: 19070657
[TBL] [Abstract][Full Text] [Related]
58. CYP3A4 Activity is Markedly Lower in Patients with Crohn's Disease.
Wilson A; Tirona RG; Kim RB
Inflamm Bowel Dis; 2017 May; 23(5):804-813. PubMed ID: 28301431
[TBL] [Abstract][Full Text] [Related]
59. Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression?
Paine MF; Ludington SS; Chen ML; Stewart PW; Huang SM; Watkins PB
Drug Metab Dispos; 2005 Mar; 33(3):426-33. PubMed ID: 15608139
[TBL] [Abstract][Full Text] [Related]
60. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age.
Fakhoury M; Litalien C; Medard Y; Cavé H; Ezzahir N; Peuchmaur M; Jacqz-Aigrain E
Drug Metab Dispos; 2005 Nov; 33(11):1603-7. PubMed ID: 16049125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
